Adakveo (Crizanlizumab)

Crizanlizumab is a medicine for people with sickle cell disease. It helps lower how often painful crises happen by stopping blood cells from sticking to the walls of blood vessels. It is given as an infusion into a vein at a clinic.

Brand names:Adakveo
Medication

What people taking Adakveo (Crizanlizumab) report

Every report comes from a Lived member, sent anonymously.

Have you tried Adakveo (Crizanlizumab) for Sickle Cell Disease?

NameHow it went

About Adakveo (Crizanlizumab)

What It's For

Crizanlizumab, sold as Adakveo, is a prescription infusion for people with sickle cell disease. It is approved in the US to reduce how often vaso-occlusive crises happen in adults and teenagers aged 16 and older. A vaso-occlusive crisis, often called a pain crisis, occurs when sickled red blood cells block small blood vessels, causing sudden, severe pain that frequently leads to an emergency visit or hospital stay. Crizanlizumab is meant to prevent crises over time; it does not treat a crisis that is already under way. The evidence for it is mixed. Its approval in 2019 rested on a one-year trial in which people taking it had fewer crises needing medical care than people given a placebo (a median of about 1.6 per year compared with 3.0). A larger follow-up trial, called STAND, found no difference in crisis rates between crizanlizumab and placebo, and the US label now states that its benefit was not established in that study. The drug remains available in the US. Hydroxyurea, a daily oral medicine, is the usual first-line treatment for preventing crises, and crizanlizumab may be added to it or used without it.

How It Works

In sickle cell disease, red blood cells, white blood cells and platelets tend to stick to the inner lining of blood vessels and to each other. These clumps slow blood flow and can trap sickled cells, which is part of how a crisis starts. P-selectin is a protein on the surface of blood vessel walls and platelets that acts like a docking point for these cells, especially when vessels are inflamed. Crizanlizumab is a monoclonal antibody, a laboratory-made protein designed to attach to one specific target. It binds P-selectin and blocks it, so blood cells have fewer places to latch on. The aim is to keep blood moving through small vessels and lower the chance that a blockage builds into a crisis. It does not change the sickle hemoglobin itself or how red blood cells are made.

Dosage & Administration

Crizanlizumab is given only by a healthcare professional, as an infusion into a vein (IV) that takes about 30 minutes, usually at an infusion center or clinic. The first two doses are given two weeks apart, and after that it is given every four weeks. The amount is calculated from body weight. If an appointment is missed, the dose is given as soon as it can be rescheduled, and the care team adjusts the timing of later doses. Crizanlizumab can be used with or without hydroxyurea, and people usually keep taking their other sickle cell medicines unless their clinician says otherwise.

Side Effects

The most common side effects in studies were headache, joint pain, back pain, nausea, abdominal pain, tiredness, fever, diarrhea, vomiting and sore throat. Some people also notice pain, swelling or itching where the IV goes in. Infusion-related reactions are the main safety concern. They can happen during an infusion or within the following day, and are most likely with the first or second infusion. Symptoms include pain, fever, nausea, vomiting, dizziness, tiredness, itching and diarrhea, and some reactions have needed a hospital stay. Because an infusion reaction can look like, or set off, a pain crisis, contact the care team right away if these symptoms start after an infusion. The infusion staff can slow or stop a reaction that begins in the clinic and may suggest medicines beforehand next time.

Interactions & Warnings

Crizanlizumab has no known drug interactions that rule out common sickle cell treatments, and it has no listed contraindications. One practical issue is blood testing: it can make platelets clump in some standard blood tubes, which can make an automated platelet count look falsely low. Tell anyone drawing blood that you receive crizanlizumab, so the lab can run the sample quickly, use a different tube or check the count under a microscope. If a reaction needs treatment, clinicians are cautious about using corticosteroids (steroid medicines such as prednisone) in people with sickle cell disease, because steroids can raise the risk of acute chest syndrome, a serious lung complication of the disease. They are still used when clearly needed, for example for a severe allergic reaction. Animal studies showed increased pregnancy loss, and there is too little human data to judge the risk. Anyone who is pregnant, planning a pregnancy or breastfeeding should weigh the benefits and risks with their hematologist, keeping in mind that sickle cell disease itself raises risks during pregnancy.

What to Expect

Crizanlizumab is a long-term, preventive treatment. Its effect is judged by how many crises happen over months, not by how someone feels after a single infusion, so it helps to keep a record of crises, emergency visits and hospital stays, including pain episodes managed at home. The label advises clinicians to reassess the treatment at least once a year and to consider stopping it if there is no clear benefit. Given the conflicting trial results, that review matters: some people may have fewer crises, while others may see no change. Regular infusions every four weeks also mean planning around clinic visits, travel and work.

Questions to Ask Your Doctor

  1. 1.Given that the larger STAND trial found no benefit over placebo, why do you think crizanlizumab is worth trying for me?
  2. 2.How does crizanlizumab compare with hydroxyurea, L-glutamine or other options for reducing my crises?
  3. 3.How will we measure whether it is working, and when would we decide to stop?
  4. 4.What should I do if I develop pain, fever or other symptoms after an infusion?
  5. 5.Should I change anything about treatment if I become pregnant or plan to breastfeed?

Last reviewed • Oct 2026

Educational content, not medical advice.